Early study data from Wave Life Sciences suggests how editing RNA may yield viable medicines. Large and small drugmakers say ...

The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for ...

An editorial by Fyodor Urnov lays out the urgent case for major reform in the regulatory appraisal of clinical therapies involving CRISPR gene therapies.

An invited Guest Editorial entitled “Give Cas a Chance,” by Fyodor Urnov, PhD, Director of Technology & Translation at the ...

Given this risk, we thought we'd take a look at whether CRISPR Therapeutics (NASDAQ:CRSP) shareholders should be worried ...

Editas, one of the oldest CRISPR-focused biotechs, is pivoting again — to a sickle cell treatment that requires editing a ...

NEWTON, Mass., Oct. 24, 2024 /PRNewswire/ -- Dash Bio, an innovator in tech-enabled services for drug development, announced ...

The pharma market shows promise as gene therapy gains momentum through rapid advancements that address complex diseases and ...

Have we entered the golden age of plant engineering?

EDT Cathie Wood’s ARK Investment bought 47.8K shares of Crispr Therapeutics (CRSP) today Published first on TheFly – the ...

Award from Highly Competitive Initiative Will Enable Ancilia to Advance Its Lead Program through IND Filing for Its First Clinical ...

What keeps some immune systems youthful and effective in warding off age-related diseases? A mouse study provides new ...